InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
81.98
(
-0.18%
)
Bitcoin
66,454.24
(
-0.28%
)
Post# of 252218
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119848
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 238530

Wednesday, 07/07/2021 11:48:09 AM

Wednesday, July 07, 2021 11:48:09 AM

Post# of 252218
ABUS starts_phase-2a_trial_testing interferon+nuke ± AB-729:

https://www.globenewswire.com/news-release/2021/07/07/2258785/14025/en/Arbutus-Receives-Authorization-to-Proceed-with-an-Investigational-New-Drug-Application-IND-for-AB-729-its-Proprietary-Subcutaneously-Delivered-RNAi-Agent.html

There will be 8-12 patients in each of four arms: with/without AB-729; and treatment duration of 12 weeks or 24 weeks.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up